A detailed history of Grandfield & Dodd, LLC transactions in Incyte Corp stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 19,525 shares of INCY stock, worth $1.34 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
19,525
Previous 18,915 3.22%
Holding current value
$1.34 Million
Previous $1.15 Million 12.57%
% of portfolio
0.08%
Previous 0.08%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$57.33 - $68.61 $34,971 - $41,852
610 Added 3.22%
19,525 $1.29 Million
Q2 2024

Aug 09, 2024

BUY
$51.18 - $63.75 $5,373 - $6,693
105 Added 0.56%
18,915 $1.15 Million
Q1 2024

May 03, 2024

BUY
$56.55 - $66.59 $23,751 - $27,967
420 Added 2.28%
18,810 $1.07 Million
Q4 2023

Jan 31, 2024

BUY
$52.16 - $64.19 $16,639 - $20,476
319 Added 1.77%
18,390 $1.15 Million
Q3 2023

Oct 25, 2023

BUY
$57.77 - $65.93 $26,863 - $30,657
465 Added 2.64%
18,071 $1.04 Million
Q2 2023

Aug 07, 2023

BUY
$60.95 - $75.51 $12,860 - $15,932
211 Added 1.21%
17,606 $1.1 Million
Q1 2023

Apr 28, 2023

BUY
$70.23 - $86.01 $24,931 - $30,533
355 Added 2.08%
17,395 $1.26 Million
Q4 2022

Jan 20, 2023

BUY
$67.18 - $84.11 $75,577 - $94,623
1,125 Added 7.07%
17,040 $0
Q3 2022

Nov 03, 2022

BUY
$66.18 - $82.86 $23,163 - $29,001
350 Added 2.25%
15,915 $1.06 Million
Q2 2022

Aug 01, 2022

BUY
$66.18 - $83.18 $12,243 - $15,388
185 Added 1.2%
15,565 $1.18 Million
Q1 2022

Apr 19, 2022

BUY
$66.02 - $79.71 $31,029 - $37,463
470 Added 3.15%
15,380 $1.22 Million
Q4 2021

Feb 08, 2022

BUY
$63.34 - $74.11 $112,111 - $131,174
1,770 Added 13.47%
14,910 $1.09 Million
Q3 2021

Oct 28, 2021

BUY
$68.67 - $84.02 $19,227 - $23,525
280 Added 2.18%
13,140 $900,000
Q2 2021

Jul 28, 2021

BUY
$79.87 - $87.53 $17,172 - $18,818
215 Added 1.7%
12,860 $1.08 Million
Q1 2021

Apr 22, 2021

BUY
$76.02 - $100.5 $8,362 - $11,055
110 Added 0.88%
12,645 $1.03 Million
Q4 2020

Jan 29, 2021

BUY
$80.74 - $97.7 $28,985 - $35,074
359 Added 2.95%
12,535 $1.09 Million
Q3 2020

Nov 03, 2020

BUY
$85.07 - $109.69 $18,970 - $24,460
223 Added 1.87%
12,176 $1.09 Million
Q2 2020

Jul 24, 2020

BUY
$74.18 - $108.93 $56,376 - $82,786
760 Added 6.79%
11,953 $1.24 Million
Q1 2020

May 14, 2020

BUY
$63.18 - $85.97 $35,886 - $48,830
568 Added 5.35%
11,193 $820,000
Q4 2019

Feb 07, 2020

BUY
$73.04 - $95.72 $64,640 - $84,712
885 Added 9.09%
10,625 $928,000
Q3 2019

Oct 30, 2019

BUY
$72.82 - $86.52 $61,532 - $73,109
845 Added 9.5%
9,740 $723,000
Q2 2019

Jul 29, 2019

BUY
$73.52 - $88.7 $47,935 - $57,832
652 Added 7.91%
8,895 $756,000
Q1 2019

Apr 26, 2019

BUY
$63.56 - $88.17 $6,737 - $9,346
106 Added 1.3%
8,243 $709,000
Q4 2018

Feb 12, 2019

BUY
$58.5 - $69.94 $9,886 - $11,819
169 Added 2.12%
8,137 $517,000
Q3 2018

Nov 02, 2018

BUY
$61.75 - $74.23 $4,631 - $5,567
75 Added 0.95%
7,968 $550,000
Q2 2018

Jul 27, 2018

BUY
$60.85 - $83.98 $4,259 - $5,878
70 Added 0.89%
7,893 $529,000
Q1 2018

May 04, 2018

SELL
$83.06 - $100.98 $9,967 - $12,117
-120 Reduced 1.51%
7,823 $652,000
Q4 2017

Feb 06, 2018

BUY
$93.56 - $116.6 $13,566 - $16,907
145 Added 1.86%
7,943 $752,000
Q3 2017

Nov 03, 2017

BUY
$109.15 - $138.27 $851,151 - $1.08 Million
7,798
7,798 $910,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Grandfield & Dodd, LLC Portfolio

Follow Grandfield & Dodd, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grandfield & Dodd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grandfield & Dodd, LLC with notifications on news.